Assessing Pro Medicus (ASX:PME) Valuation After Ohio State Wexner Contract Renewal

Simply Wall St.02:21

Pro Medicus (ASX:PME) shares are back in focus after the company secured a five year, A$16 million contract renewal with The Ohio State University Wexner Medical Center, which includes additional ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641814223?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-06-06 02:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641814223","market":"hk","top_or_hot":-1,"title":"Assessing Pro Medicus (ASX:PME) Valuation After Ohio State Wexner Contract Renewal","media":"Simply Wall St.","content":"<div>\n<p>Pro Medicus (ASX:PME) shares are back in focus after the company secured a five year, A$16 million contract renewal with The Ohio State University Wexner Medical Center, which includes additional ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicus-asxpme-valuation-after-ohio-state-wexn\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Pro Medicus (ASX:PME) Valuation After Ohio State Wexner Contract Renewal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Pro Medicus (ASX:PME) Valuation After Ohio State Wexner Contract Renewal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-06 02:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicus-asxpme-valuation-after-ohio-state-wexn><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pro Medicus (ASX:PME) shares are back in focus after the company secured a five year, A$16 million contract renewal with The Ohio State University Wexner Medical Center, which includes additional ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicus-asxpme-valuation-after-ohio-state-wexn\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1894683264.USD","symbol_name":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicus-asxpme-valuation-after-ohio-state-wexn","article_id":"2641814223","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicus-asxpme-valuation-after-ohio-state-wexn","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641814223","pubTimestamp":1780683712,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pro Medicus (ASX:PME) shares are back in focus after the company secured a five year, A$16 million contract renewal with The Ohio State University Wexner Medical Center, which includes additional imaging modules and higher recurring fees.\nSee our latest analysis for Pro Medicus.\nThat renewal has arrived at a time when short term momentum in the stock is strong, with a 1 day share price return of 4.03% and a 7 day share price return of 25.24%. However, the year to date share price return is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","STT":"道富银行","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","PME.AU":"PRO MEDICUS LTD","BK4135":"资产管理与托管银行","BK7094":"医疗保健技术"},"translate_title":"俄亥俄州Wexner合同续签后评估Pro Medicus(ASX：PME)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":1.5,"STT":1.5},"content_text":"Pro Medicus (ASX:PME) shares are back in focus after the company secured a five year, A$16 million contract renewal with The Ohio State University Wexner Medical Center, which includes additional imaging modules and higher recurring fees. See our latest analysis for Pro Medicus. That renewal has arrived at a time when short term momentum in the stock is strong, with a 1 day share price return of 4.03% and a 7 day share price return of 25.24%. However, the year to date share price return is down 25.60% and the 1 year total shareholder return is down 39.77%, even though the 3 year and 5 year total shareholder returns remain very large in absolute terms. If Pro Medicus has you looking more closely at healthcare imaging and AI, you might also want to scan a wider field of 9 healthcare AI stocks With Pro Medicus now trading at A$165.64, after a sharp rebound but with the share price still down over the past year, a key question is whether the stock is now undervalued or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 16% Undervalued According to the most followed narrative, Pro Medicus has a fair value of A$196.78 per share, which sits above the latest close at A$165.64 and frames the recent rebound in a different light.  At $120, the stock offers an asymmetric setup, you are not buying a distressed company, you are buying a best-in-class franchise that has temporarily disappointed quarterly expectations in a business where revenue is inherently lumpy. The contract backlog, the renewal rate, the margin profile, and the expanding addressable market have not changed. The price has.  Read the complete narrative. Curious what sits behind that confidence? The narrative leans on robust revenue expansion, thick margins and a punchy profit multiple. One set of assumptions brings those together into that A$196.78 fair value. The detail is where it gets interesting. Result: Fair Value of A$196.78 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this relies heavily on ongoing contract wins and premium pricing, so any slowdown in hospital demand or pricing pressure could quickly challenge that case for undervaluation. Find out about the key risks to this Pro Medicus narrative. Another View: Rich Multiples Question the Undervaluation Story The user narrative leans on growth and quality to argue Pro Medicus is around 16% undervalued at A$196.78 per share. Yet on simple P/E math the stock looks expensive, trading on 73.7x compared with a fair ratio of 28.3x, a peer average of 28.8x and a global Healthcare Services average of 26.6x. That gap leaves very little room for disappointment, so which lens do you trust more when expectations are this high? See what the numbers say about this price — find out in our valuation breakdown. ASX:PME P/E Ratio as at Jun 2026Next Steps Mixed signals so far, right? A rich multiple on one side and a popular undervaluation story on the other. If you want to move quickly and base your own view on the underlying data, take a closer look at the 2 key rewards and 2 important warning signs Looking for more investment ideas? If you stop with just one stock, you could miss other opportunities that fit your goals, so widen your search and stress test your thinking with a few focused screens.  Target quality at a discount by scanning 7 high quality undervalued stocks that pair strong fundamentals with lower implied pricing. Prioritise resilience by checking 6 resilient stocks with low risk scores that score well on stability and downside protection. Hunt for tomorrow’s standouts by reviewing the screener containing 12 high quality undiscovered gems before they are widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641814223","isCrawlerRequest":true}